ClinicalTrials.gg
CompletedNCT02548143PerSept3Updated Feb 25, 2022Results posted

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

A Phase 3 interventional study of Coagulation Factor VIIa (Recombinant) in Hemophilia, sponsored by Laboratoire français de Fractionnement et de Biotechnologies. Completed at 9 sites in 6 countries. Open to male participants aged 6 Months to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-25.

Sponsored by Laboratoire français de Fractionnement et de Biotechnologies · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
6 Months to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.

Enrollment
15th of 19
12 · median 24
Started
2016
the only one that year
Phase 3
5 of 20
none open now
Registered
18th of 20
by date
Lead sponsor
2 of 20
Laboratoire français de Fractionnement et de Biotechnologies

Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 3, and was the 18th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 6 Months to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing recombinant FVIIa in Hemophilia A, or all of them as a file.
02

Study summary

The purpose of this study, PerSept 3, is to evaluate LR769 for the prevention of excessive bleeding and achievement of hemostasis in congenital hemophilia A or B patients who have inhibitors to Factor VIII or Factor IX , are aged 6 months to 75 years, inclusive; and who are undergoing elective surgical or other invasive procedures. Administration of LR769 will be performed just prior to surgery/procedure and will be repeated during and after the surgery/procedure to achieve and maintain adequate hemostasis as determined by the investigator's judgment.

Read the detailed description

This study is an international, multicenter, single-arm, Phase 3 study. Patients aged 6 months to 75 years, inclusive, who have congenital hemophilia A or B with inhibitors to Factor VIII or Factor IX and who are scheduled for an elective surgical or other invasive procedure will be enrolled. Both major and minor surgical or other invasive procedures are allowed in the study.

Initial Treatment: Regardless of procedure, patients who meet all eligibility criteria will receive an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For a minor elective surgery or other minor invasive procedure, a dose of 75 μg/kg will be used as the initial dose; for a major elective surgery or other major invasive procedure, a dose of 200 μg/kg of LR769 will be used as the initial dose. For both minor and major procedures, administration will be repeated no more frequently than every 2 hours (±5 minutes) at a dose of 75 μg/kg during and after surgery or invasive procedure.

Treatment for Major Surgical Procedures: The initial dose of LR769 will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure. The minimum duration of LR769 treatment for major procedures will be 5 days and dosing frequency will be followed according to the guidelines specified in the protocol.

Treatment for Minor Surgical or Other Invasive Procedures: The initial dose of LR769 will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours. The minimum duration of LR769 infusion for minor procedures will be 2 days, except for certain procedures that may not require this duration of treatment to achieve hemostasis as noted in the protocol. Dosing frequency will be according to the guidelines specified in protocol for minor surgical or other invasive procedures.

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
6 Months to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each patient must meet the following criteria to be enrolled in this study:

  1. be male with a diagnosis of congenital hemophilia A or B of any severity
  2. have one of the following:

    1. a positive inhibitor test Bethesda Unit (BU) ≥5 (as confirmed at screening by the institutional lab), OR
    2. a BU \<5 but expected to have a high anamnestic response to FVIII or FIX, as demonstrated from the patient's medical history, precluding the use of FVIII or FIX products to treat or prevent bleeding, OR
    3. a BU \<5 but expected to be to increased dosing of FVIII or FIX, as demonstrated from the patient's medical history, precluding the use of FVIII or FIX products to treat or prevent bleeding episodes
  3. be ≥6 months to ≤75 years of age; different age restrictions may apply per local regulation and ethical considerations (enrollment of children \<12 years of age will not begin until after review of data from the PERSEPT 2 study by the DMC)
  4. be scheduled for an elective surgical or other invasive procedure
  5. be capable of understanding and willing to comply with the conditions of the protocol OR in the case of a patient \<18 years of age, parent(s)/legal guardian(s) must be capable of understanding and willing to comply with the conditions of the protocol
  6. have read, understood, and provided written (patient and/or parent(s)/legal guardian(s) if the patient is \<18 years of age) or Assent, if applicable

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study:

  1. have any coagulation disorder other than hemophilia A or B
  2. be (ie, the patient should not be receiving systemic immunosuppressive medication; cluster of differentiation 4 (CD4) counts at screening should be >200/µL)
  3. known intolerance to LR769 or any of its
  4. currently receiving immune tolerance induction (ITI) therapy
  5. have a known allergy or to rabbits
  6. have a count\<100,000/µL
  7. have received an drug within 30 days of the planned first LR769 administration , or is expected to receive such drug during participation in this study (with the exception of patients who are or were participating in another LR769 study, eg, a study assessing the treatment of bleeding episodes with LR769)
  8. have a hepatic ( (AST) and/or alanine aminotransferase (ALT) >3 times the (ULN)) and/or renal impairment (creatinine >2 times the ULN)
  9. have a history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, , deep venous thrombosis (DVT) or pulmonary embolism (PE)) within 2 years prior to the planned first dose of LR769, uncontrolled arrhythmia, or current (NYHA) functional classification score of stages II - IV
  10. have an active (those with non-melanoma skin cancer are allowed)
  11. have any life-threatening disease or other disease or condition which, according to the investigator's judgment, could imply a potential hazard to the patient, or interfere with the trial participation or trial outcome (eg, a history of non-responsiveness to bypassing products)
  12. be using aspirin, NSAIDS, herbs, natural medications, or other drugs with platelet inhibitory properties within one week prior to surgery and for the duration of treatment with LR769
  13. have active gastric or duodenal ulcer disease
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Coagulation Factor VIIa (Recombinant)

    A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.

    Biological: Coagulation Factor VIIa (Recombinant)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Surgical or Other Invasive Procedures Defined as "Good" or "Excellent" Response to LR769 Treatment as Assessed by the Investigator, Based on the Totality of the Assessments Performed on the Patient

    The final assessment was performed by the investigator at the study center 48 hours after the last dose of LR769 and was based upon the totality of the assessments performed on the patient at each time point. Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required. Good: postoperative blood loss greater, but not substantially greater than expected, following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion.

    Time frame: 48 (±4) hours after the last administration of LR769

Secondary outcomes

  1. Percentages of Success as Defined as the Combination of "Good" and "Excellent" Responses by the Investigator or Designee

    Good: postoperative blood loss greater than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required

    Time frame: 24 hours after procedure completion

  2. Percentages of Success as Defined as the Combination of "Good" and "Excellent" Responses by the Investigator or Designee

    Good: postoperative blood loss greater than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required

    Time frame: 72 hours after procedure completion

07

Results

Posted Sep 6, 2019

Participant flow

Participant flow — Overall Study
MilestoneMajor Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)
Started66
Completed55
Not completed11
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercentage of Surgical or Other Invasive Procedures Defined as "Good" or "Excellent" Response to LR769 Treatment as Assessed by the Investigator, Based on the Totality of the Assessments Performed on the Patient

The final assessment was performed by the investigator at the study center 48 hours after the last dose of LR769 and was based upon the totality of the assessments performed on the patient at each time point. Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required. Good: postoperative blood loss greater, but not substantially greater than expected, following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion.

Time frame:
48 (±4) hours after the last administration of LR769
Reported as:
Count of units · Surgeries
Percentage of Surgical or Other Invasive Procedures Defined as "Good" or "Excellent" Response to LR769 Treatment as Assessed by the Investigator, Based on the Totality of the Assessments Performed on the Patient
SurgeriesMajor Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)
Successes45
Failures20
SecondaryPercentages of Success as Defined as the Combination of "Good" and "Excellent" Responses by the Investigator or Designee

Good: postoperative blood loss greater than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required

Time frame:
24 hours after procedure completion
Reported as:
Count of units · Surgeries
Percentages of Success as Defined as the Combination of "Good" and "Excellent" Responses by the Investigator or Designee
SurgeriesMajor Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)
Successes46
Failures00
SecondaryPercentages of Success as Defined as the Combination of "Good" and "Excellent" Responses by the Investigator or Designee

Good: postoperative blood loss greater than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure, not explained by a surgical/medical issue other than hemophilia; no unexpected need for blood component transfusion Excellent: postoperative blood loss similar to or less than expected following this type of procedure in a patient who does not have a bleeding disorder and who is undergoing the same surgical or other invasive procedure; no blood component transfusion is required

Time frame:
72 hours after procedure completion
Reported as:
Count of units · Surgeries
Percentages of Success as Defined as the Combination of "Good" and "Excellent" Responses by the Investigator or Designee
SurgeriesMajor Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)
Successes52
Failures00

Adverse events

Collected over Adverse Events (AEs) were collected from the time of signing of the informed consent/assent until resolution or 30 days after the last dose of LR769 or early termination, whichever came first.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventMajor Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)
Haemorrhagic AnaemiaBlood and lymphatic system disorders1/60/6
Gastrointestinal HaemorrhageGastrointestinal disorders1/60/6
Most frequent other events
Showing 10 of 16
Most frequent other events
EventMajor Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)
Procedural PainInjury, poisoning and procedural complications5/60/6
AnaemiaBlood and lymphatic system disorders2/60/6
Anaemia PostoperativeInjury, poisoning and procedural complications2/60/6
Wound SecretionInjury, poisoning and procedural complications1/62/6
Abdominal PainGastrointestinal disorders1/60/6
NauseaGastrointestinal disorders1/60/6
Catheter Site PainGeneral disorders0/61/6
Postoperative Wound InfectionInfections and infestations1/60/6
Post Procedural HaematomaInjury, poisoning and procedural complications1/60/6
Post Procedural HaemorrhageInjury, poisoning and procedural complications1/61/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)Total
<=18 years246
Between 18 and 65 years426
>=65 years000
Age, Continuous
Age, Continuous(years)Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)Total
Mean34.0 ± 20.1916.0 ± 15.5225.0 ± 19.57
Sex: Female, Male
Sex: Female, Male(Participants)Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)Total
Female000
Male6612
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)Total
Hispanic or Latino101
Not Hispanic or Latino5611
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American134
White538
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)Total
Ukraine336
South Africa134
Mexico101
Russia101
Weight
Weight(kg)Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)Total
Mean54.17 ± 25.97436.72 ± 21.50645.44 ± 24.494
Height
Height(cm)Major Surgery (LR769 Initial Dose 200 μg/kg; Then 75 μg/kg)Minor Surgery (LR769 Initial Dose 75 μg/kg; Then 75 μg/kg)Total
Mean156.3 ± 22.50137.8 ± 34.02147.1 ± 29.13

1 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • UT Southwestern Medical Center
    Dallas, Texas 75235, United States
  • Dr. Jose Eleuterio Gonzalez Monterrey University Hospital
    Monterrey, Nuevo Leon 64460, Mexico
  • Hematology Research Center of the Russian Academy of Medical Sciences
    Moscow, 125167, Russian Federation
  • Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care
    Parktown, Gauteng 2193, South Africa
  • Worthwhile Clinical Trials, Lakeview Hospital
    Benoni, South Africa
  • University and Polytechnic Hospital La Fe, Hemostasis and Thrombosis Unit
    Valencia, 46026, Spain
  • City Scientific-Practical center for diagnosics
    Kiev, Ukraine
  • National Specialized Children's Hospital OKHMATDYT, Centre for Hemostatic Pathology
    Kyiv, Ukraine
  • Institute of Blood Pathology and Transfusion Medicine
    Lviv, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Aug 2017, 11 months.

Results were first posted in Sep 2019, 2 years 1 month after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 11 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2015
First posted
Sep 14, 2015
StartActual
Aug 25, 2016
Primary completionActual
Aug 6, 2017
CompletionActual
Aug 31, 2017
Results first posted
Sep 6, 2019
Last update
Feb 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02548143
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Collaborators
LFB USA, Inc.
Responsible party
Sponsor
First posted
Sep 14, 2015
Start date
Aug 25, 2016
Primary completion
Aug 6, 2017
Completion
Aug 31, 2017
Results posted
Sep 6, 2019
Last update
Feb 25, 2022

Study contacts

Miguel Escobar, MD
principal investigator · Memorial Hermann Texas Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion